Unión Europea - eslovaco - EMA (European Medicines Agency)

horizon therapeutics ireland dac - inebilizumab - neuromyelitis optica - imunosupresíva - uplizna is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (nmosd) who are anti-aquaporin 4 immunoglobulin g (aqp4-igg) seropositive (see section 5.

Eslovaquia - eslovaco - ŠÚKL (Štátny ústav pre kontrolu liečiv)

pharmagen cz s.r.o., Česká republika - everolimus - 44 - cytostatica

Eslovaquia - eslovaco - ŠÚKL (Štátny ústav pre kontrolu liečiv)

pharmagen cz s.r.o., Česká republika - everolimus - 44 - cytostatica

Eslovaquia - eslovaco - ŠÚKL (Štátny ústav pre kontrolu liečiv)

pharmagen cz s.r.o., Česká republika - everolimus - 44 - cytostatica

Unión Europea - eslovaco - EMA (European Medicines Agency)

ucb pharma sa - certolizumab pegol - crohnova choroba - imunosupresíva - cimzia, in combination with methotrexate (mtx), is indicated for the treatment of moderate to severe, active rheumatoid arthritis (ra) in adult patients when the response to disease-modifying antirheumatic drugs (dmard) including methotrexate, has been inadequate. cimzia sa môže podávať ako monotherapy v prípade intolerancie na metotrexát, alebo keď pokračovanie liečby s metotrexátom nevhodné. cimzia has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function, when given in combination with methotrexate.